Cargando…

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab

A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anas...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Erin D., Macdonald, D. Blair, Elkeilani, Akram M., Asmis, Timothy R.
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918857/
https://www.ncbi.nlm.nih.gov/pubmed/20740172
http://dx.doi.org/10.1159/000229245
_version_ 1782185155330310144
author Powell, Erin D.
Macdonald, D. Blair
Elkeilani, Akram M.
Asmis, Timothy R.
author_facet Powell, Erin D.
Macdonald, D. Blair
Elkeilani, Akram M.
Asmis, Timothy R.
author_sort Powell, Erin D.
collection PubMed
description A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab.
format Text
id pubmed-2918857
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29188572010-08-25 A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab Powell, Erin D. Macdonald, D. Blair Elkeilani, Akram M. Asmis, Timothy R. Case Rep Oncol Published: July 2009 A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab. S. Karger AG 2009-07-17 /pmc/articles/PMC2918857/ /pubmed/20740172 http://dx.doi.org/10.1159/000229245 Text en Copyright © 2009 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: July 2009
Powell, Erin D.
Macdonald, D. Blair
Elkeilani, Akram M.
Asmis, Timothy R.
A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title_full A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title_fullStr A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title_full_unstemmed A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title_short A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
title_sort case of appendiceal adenocarcinoma with clinical benefit from folfox and bevacizumab
topic Published: July 2009
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918857/
https://www.ncbi.nlm.nih.gov/pubmed/20740172
http://dx.doi.org/10.1159/000229245
work_keys_str_mv AT powellerind acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT macdonalddblair acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT elkeilaniakramm acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT asmistimothyr acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT powellerind caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT macdonalddblair caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT elkeilaniakramm caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab
AT asmistimothyr caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab